All analyses
AI analysis

Sunshine Holdings PLC: research report

Fairly valuedbearishOct 22, 2026

Evidence points bearish: June net profit fell 15.2% despite higher revenue and the shares trade near their most expensive earnings valuation on record. The counterweight is a USD 20 million pharmaceutical plant investment aimed at 2028 operations.

Reports without a focus are public, one per stock per day. Generation usually takes about 15 minutes, and we'll notify you when it's ready.

Why bearish

  • June-quarter net profit fell 15.2% year-on-year as operating margin dropped to the worst of seven comparable June quarters.
  • The P/E is more expensive than 99% of days since July 2018, while profit attributable to shareholders has weakened.
  • The dividend payout ratio is 131.4%, meaning the trailing distribution exceeds trailing earnings.

Against this. The Zydus Sunshine Lifesciences JV is investing USD 20 million in a local pharmaceutical facility targeted for commercial operations in 2028.

Operating margin
16.8%sector 9.7%
from 17.4% a year earlier
Net margin
10.8%sector 3.0%
from 8.1% a year earlier, revenue +32.0%
Return on equity
17.0%
twelve months to Sep 30, 2026, unaudited
P/E
17.3sector 14.2
earnings Rs 1.76 per share, year to Sep 2026
P/B
2.94sector 1.20
book Rs 10.38 per share
Dividend yield
5.57%sector 2.08%
96.6% of earnings paid out

Current figures, updated daily from filings to Sep 30, 2026. The report below was written on Oct 22, 2026. Sector figures are the median of 22 listed companies in the same sector.

Overview

Sunshine Holdings combines healthcare, consumer goods and agribusiness operations, with healthcare spanning pharmaceutical distribution, retail, devices and local manufacturing. The key change is that sales are still expanding, but the latest June quarter converted a smaller share of those sales into operating profit and net profit. Starting from the market-wide Fairly valued band, that evidence moves the assessment to bearish because earnings quality has weakened while the current earnings multiple is near its own historical extreme.

Price performance

At LKR 27.00 on 22 October 2026, the share was down 18.4% over one year against an 11.7% fall in the ASPI, so it has lagged the broader market over that period. It sits near the bottom of its 52-week range; both recent volatility and trading volume are below Sunshine's own recent norms, indicating quieter trading rather than an unusually active sell-off.

The three-year record shows two falls of 15% or more, the deepest 31%, which has not yet recovered. Median daily turnover was LKR 6.7 million; a LKR 1 million order is about 15% of what trades on a typical day, a noticeable part of a day's trading.

Valuation

The P/E is 19.7 times, meaning the market price is LKR 19.7 for each LKR 1 of trailing profit, while the P/B is 2.74 times, or LKR 2.74 for each LKR 1 of net assets. Both sit toward the expensive end of diversified holdings, with P/E at the 75th percentile and P/B at the 85th percentile of available sector peers. A trailing ROE of 14.0% supports some premium to book value, but not the full contrast with sector medians when margins are falling.

Against Sunshine's own record, the P/E is more expensive than 99% of days since July 2018 and P/B more expensive than 83% of days. The 6.7% dividend yield is high relative to peers, and dividends rose from LKR 0.98 in FY2025 to LKR 1.80 in FY2026, but the payout exceeded trailing earnings. A buyer at this price is therefore relying on earnings recovery as well as the dividend being sustained; the latest quarter supplied 24.6% of trailing EPS despite a lower net margin than a year earlier.

News and sentiment

Coverage is normal rather than unusually intense, with five company articles in the past month. Of nine material articles over 90 days, seven were positive, one negative and one neutral.

Reported on 16 October, the Zydus Sunshine Lifesciences JV signed a BOI agreement for a phased USD 20 million Horana manufacturing facility, with commercial operations targeted for 2028. The disclosed investment establishes future manufacturing capacity, but the announcement gives no revenue, margin or ownership contribution that would allow its earnings effect to be sized. Separately, Sunshine Healthcare acquired about 22% of Doc990 for a reported total outlay of LKR 410.8 million, giving it a strategic minority interest rather than control.

Financials

June-quarter revenue rose 16.6% year-on-year, but operating profit fell 7.7% and net profit fell 15.2%. Gross margin was 28.1% versus 31.8% a year earlier, operating margin 13.2% versus 16.6%, and net margin 7.6% versus 10.4%. Each was the worst of seven comparable June quarters, so the profit behind the current share price rests on a materially weaker conversion of sales than Sunshine has recorded in prior June periods.

Below operating profit, LKR 1.0 billion was absorbed by finance costs, tax, associates and other non-operating items, slightly more than a year earlier. Total equity was LKR 27.1 billion against LKR 26.7 billion a year earlier, while the ordinary share count was unchanged year-on-year at about 2.0 billion. The 2025 one-for-four subdivision mechanically changed older per-share figures, so operating and absolute-profit trends are more informative than unadjusted historic EPS.

The latest filed period is June 2026. No newer financial result is present in the news flow, so the margin deterioration remains the latest reported operating evidence.

Risks

The largest risk is that lower margins persist while the valuation still assumes a substantial earnings base. Annual operating cash conversion was 0.84 times in March 2026, meaning operating cash flow was below operating profit, so reported profit did not fully arrive as cash.

Debt was 47.8% of owners' equity at March 2026, the measure of borrowing against shareholders' funds, although interest cover was 12.94 times, meaning operating profit covered the interest bill almost thirteen times. The current ratio was 1.73 times, so current assets including inventories and customer receivables exceeded bills due within a year, but this is less liquid protection than the prior year's ratio.

Minority shareholders received 39.4% of FY2026 group profit. Group net profit therefore overstates the earnings attributable to the ordinary shares being valued. Healthcare represents 57% of segment revenue, leaving the group meaningfully exposed to the sector backdrop of regulatory pricing pressure and competitive additions to domestic manufacturing capacity.

Outlook

As at 22 October 2026, the next specific evidence point is the September 2026 interim filing, expected between 6 and 14 November. It will show whether the June margin compression extended into the following quarter or whether higher revenue again translated into stronger profit.

The Zydus facility is a longer-dated operational development, with reported commercial operations targeted for 2028. The available data cannot quantify its eventual sales, margins, funding structure or Sunshine's share of its earnings, so it cannot yet offset the current evidence of weaker profitability.

About this report. Generated on Oct 22, 2026 from market data up to Oct 22, 2026, 9 material news articles over 90 days and financials to Jun 30, 2026, and scored 51 of 100 on value (fairly valued) when it was written. Every figure is drawn from EquityLK's own data on this company. AI research can contain errors, so treat it as a starting point, not investment advice.

Previous reports